1. Abola, M. V., & Prasad, V. (2016). Characteristics and conflicts of public speakers at meetings of the oncologic drugs advisory committee to the US Food and Drug Administration. JAMA Internal Medicine, 176(3), 389–391. ://MEDLINE:26831527.
2. Association of the British Pharmaceutical Industry. (2019). ABPI code of practice for the pharmaceutical industry. http://www.pmcpa.org.uk/thecode/Documents/ABPI%20Code%20of%20Practice%202019.pdf
3. Agrawal, S., Brennan, N., & Budetti, P. (2013). The Sunshine Act—Effects on physicians. The New England Journal of Medicine, 368(22), 2054–2057. https://doi.org/10.1056/NEJMp1303523. http://www.ncbi.nlm.nih.gov/pubmed/23718163
4. Alzheimer’s Association. (2021a, June 7). Alzheimer’s Association welcomes FDA approval of Aducanumab. Press Release. Altzheimer’s Association. Accessed Nov 10. https://www.alz.org/news/2021/alzheimers-association-fda-approval-aducanumab.
5. Alzheimer’s Association. (2021b). Pharmaceutical industry contributions: FY20. Accessed Nov 18. https://www.alz.org/media/Documents/Pharmaceutical-Industry-Contributions-FY20.pdf